Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor.

Anticancer research - 1 Jul 2024

Okabe Hirohisa, Masuda Toshiro, Nitta Hidetoshi, Tomita Masahiro, Ono Asuka, Kuroda Daisuke, Kuroki Hideyuki, Hirota Masahiko, Hibi Taizo, Baba Hideo, Sugita Hiroki

Abstract excerpt

BACKGROUND/AIM: Genomic examination of tumor tissue has been clinically accepted, and the identification of actionable mutations for molecular-targeted therapy may provide substantial survival benefit for patients with advanced malignancies. CASE REPORT: A female patient in her 60s showed a stenosis of the afferent loop of the small intestine because of circumferential metastatic tumor 14 months after curative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Duct Neoplasms

Share to Cholangiocarcinoma

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Treatment Outcome

Source

Identifiers

PMID: 38925819
DOI: 10.21873/anticanres.17135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor.PMID 38925819Read ↗

Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.Semantic proximity Read ↗

Exceptional response to pembrolizumab in HER2-positive gallbladder carcinoma with high tumor mutational burdenSemantic proximity Read ↗

Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6.Semantic proximity Read ↗

Exceptional Response to Pembrolizumab in HER2-Positive Gallbladder Carcinoma with High Tumor Mutational Burden.Semantic proximity Read ↗

TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Successful Treatment of Metastatic Gallbladder Carcinoma with a High Tumor Mutational Burden Using Pembrolizumab.Semantic proximity Read ↗

Mutation spectrum associated with metastasis of advanced cholangiocarcinoma.Semantic proximity Read ↗

Complete Response for Adding Pyrotinib to Pembrolizumab and Lenvatinib for HER2 Positive Advanced Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.Semantic proximity Read ↗

Comprehensive Cancer Genomic Profiling of Liver Metastasis Led to the Unexpected Identification of Colorectal Cancer.Semantic proximity Read ↗

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Pathological Complete Response after Pembrolizumab Treatment for Unresectable Perihilar Cholangiocarcinoma with High Microsatellite Instability: A Case ReportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.